Hydroxyurea and Anagrelide Combination Therapy in Patients with Chronic Myeloproliferative Diseases Resistant or Intolerant to Monotherapy

Christoforidou, Anna; Pantelidou, Despoina; Anastasiadis, Athanasios; Goutzouvelidis, Aggelos; Margaritis, Dimitrios; Kotsianidis, Ιoannis; Spanoudakis, Emmanuil; Kaloutsi, V.; Bourikas, George; Tsatalas, Costas

doi:10.1159/000189381

Cited by 14 publications

(16 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There have been a few studies regarding the efficacy of anagrelide and hydroxyurea combination therapy. 25,29 Most studies consisted of patients for whom anagrelide was added to hydroxyurea. The present study showed that favorable platelet counts could be achieved in patients for whom hydroxyurea was added to anagrelide, which suggested that the combination therapy provides good control of platelet count and tolerability.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of anagrelide as a first‐line drug in cytoreductive treatment‐naïve essential thrombocythemia patients in a real‐world setting

Ito

Hashimoto

Tanaka

et al. 2019

European J of Haematology

View full text Add to dashboard Cite

Objective: This study aimed to retrospectively assess the efficacy and safety of anagrelide in cytoreduction therapy-naïve essential thrombocythemia (ET) patients in a real-world setting.Method: Data from 53 ET patients who received anagrelide as a first-line therapy were reviewed for patient characteristics, antiplatelet status, cytoreduction status, therapeutic effects, adverse events, thrombohemorrhagic event development, progression to myelofibrosis or acute leukemia, and cause of death. Results:The rate of achieving a platelet count of <600 × 10 9 /L during anagrelide monotherapy was 83.0%. Adverse events occurred in 32 of 53 patients, and tended to be slightly more severe in patients with cardiac failure; however, they were mostly tolerable. The therapeutic effect of anagrelide was consistent, regardless of genetic mutation profiles. The incidence of anemia as an adverse event was significantly higher in the CALR mutation-positive group. Favorable platelet counts were also achieved in patients for whom hydroxyurea was introduced as a replacement for anagrelide or in addition to anagrelide because of unresponsiveness or intolerance to treatment. Conclusion:In Japanese cytoreduction therapy-naïve ET patients, anagrelide administration as a first-line therapy demonstrated favorable effects in reducing platelet counts, and its safety profile that was generally consistent with those in previous reports. K E Y W O R D S anagrelide, essential thrombocythemia, first-line, treatment | 117 ITO eT al. Complete response, n (%) 27 (50.9) Partial response, n (%) 18 (34.0) No response, n (%) 8 (15.1) AEs (≥5% of patients) Palpitations, n (%) 14 (26.4) Headache, n (%) 11 (20.8) Anemia, n (%) 10 (18.9) Diarrhea, n (%) 4 (7.5) Cardiac failure, n (%) 3 (5.7) AEs (grade 3) Anemia, n (%) 2 (3.8) Cardiac failure, n (%) 2 (3.8) Abbreviations: AE: adverse event; SD: standard deviation.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of anagrelide as a first‐line drug in cytoreductive treatment‐naïve essential thrombocythemia patients in a real‐world setting

Ito

Hashimoto

Tanaka

et al. 2019

European J of Haematology

View full text Add to dashboard Cite

show abstract

“…anagrelide or interferon. There is emerging experience with the combination of anagrelide and HC which suggests benefit in this group of patients (Christoforidou et al , 2008; D’adda et al , 2008).…”

mentioning

confidence: 99%

Guideline for investigation and management of adults and children presenting with a thrombocytosis

et al. 2010

View full text Add to dashboard Cite

“…Su utilidad solo ha sido comunicada en un grupo de 16 pacientes con PV, MF y TE, que fueron tratados con anagrelida junto con hidroxicarbamida, en los cuales la trombocitosis fue controlada en el 88% de los pacientes tratados 50 .…”

Section: Cambios De Medicación Y Tratamiento Combinadounclassified

Tratamiento del paciente con trombocitemia esencial

Ramirez

García-Sánchez

Plaza³

2013

Medicina Clínica

View full text Add to dashboard Cite

Hydroxyurea and Anagrelide Combination Therapy in Patients with Chronic Myeloproliferative Diseases Resistant or Intolerant to Monotherapy

Cited by 14 publications

References 11 publications

Efficacy and safety of anagrelide as a first‐line drug in cytoreductive treatment‐naïve essential thrombocythemia patients in a real‐world setting

Efficacy and safety of anagrelide as a first‐line drug in cytoreductive treatment‐naïve essential thrombocythemia patients in a real‐world setting

Guideline for investigation and management of adults and children presenting with a thrombocytosis

Tratamiento del paciente con trombocitemia esencial

Contact Info

Product

Resources

About